The Medicines Company (MDCO)

This drug maker hammered analysts’ earnings estimates, posting EPS of $2.62 last quarter, vs. the -$1.16 previously forecast. Analysts are forecasting double-digit growth rates for the rest of this year. The Medicines Company (MDCO)From The Medical Technology Stock Letter On its Q2 quarterly call, The Company...
Read More

Novavax, Inc. (NVAX)

This biotech missed analysts’ forecasts last quarter, losing $0.29 per share, compared to the estimated loss of $0.15. However, clinical trials are promising, and a takeover/partnership could soon be in the works. Two analysts have raised their 2017 earnings estimates in the past days. Novavax,...
Read More

Top Stocks to Buy this Year

Every year, I ask our contributors to Wall Street’s Best Dividend Stocks and Wall Street’s Best Investments to select the one investment that they believe will be their biggest winner that year. And earlier this month, I published the winners in our special Picks...
Read More

Wall Street’s Best Investments Top Picks 2015

Congratulations to all of our contributors for their diligence and perseverance in finding winning stocks, and kudos to John McCamant of Medical Technology Stock Letter whose Top 2015 Pick led the way, with gains of 60.54%! Wall Street’s Best Investments Top Picks 2015 Three of four...
Read More

Medical Technology Stock Letter

The Medical Technology Stock Letter (MTSL) provides solid investment advice based on company and industry fundamentals. Our thirty years of experience in providing investment advice for this unique and volatile sector gives MTSL and YOU the edge. Our insistence on thorough research and of...
Read More

Cellular Biomedicine Group Inc. (CBMG)

This drug company develops treatments for cancerous and degenerative diseases in Greater China. The listing of the shares was just upgraded from the NASDAQ Capital Market to the NASDAQ Global Market, which should bring additional exposure for the company. Cellular Biomedicine Group Inc. (CBMG) from Medical...
Read More

Pharmacyclics (PCYC)

As I mentioned in my blog post last week, here is an update on the PCYC/ABBV merger. Bottom line recommendation: hold onto your ABBV stock, post-merger. Hold Pharmacyclics (PCYC) from The Medical Technology Stock Letter Updated from Investment Digest 759, July 23, 2014 Mid-Year Top Picks may...
Read More

Sangamo Biosciences Inc. (SGMO)

Analysts at JP Morgan just initiated coverage on this biotech with an “overweight” rating. And five of its scientists were also recognized by Thomson Reuters as being “Among Most Highly Cited Researchers Worldwide Of 2014”. Sangamo Biosciences Inc. (SGMO) from The Medical Technology Stock Letter The call...
Read More

Pharmacyclics (PCYC)

Today’s 2014 Top Picks update is a biotech whose earnings estimates are trending up. This contributor has also increased his price target for the shares. Pharmacyclics (PCYC) from The Medical Technology Stock Letter In January, Pharmacyclics (PCYC) released highly positive data from the RESONATE trial, the Phase...
Read More

Novavax (NVAX)

This biotech company just completed a successful Phase 2 clinical trial for its respiratory illness vaccine for women of childbearing age. Please note that shares of biotech companies are speculative in nature and should be allocated to a small percentage of your overall (NVAX) from...
Read More

OncoGenex Pharmaceuticals (OGXI)

This biopharmaceutical company has two drug candidates in clinical development across multiple oncology therapeutic areas and a candidate in pre-clinical development. OncoGenex’Pharmaceuticals (OGXI) from The Medical Technology Stock Letter OncoGenex Pharmaceuticals’ (OGXI ) custirsen could dominate second-line hormone resistant prostate cancer (HRPC) therapy. Medivation’s Xtandi has positive...
Read More

Coronado Biosciences (CNDO)

Today we have one more mid-year update on a Top Pick for 2013, from The Medical Technology Stock Letter Analyst John McCamant. For new subscribers, his Top Pick is nearly buyable at current levels; a market pullback in the next day or two provide...
Read More

Sell Alert: Teva Pharmaceutical Industries Ltd. (TEVA)

TEVA was recommended by Medical Technology Stock Letter at $38.11 in Dividend Digest issue 229, dated October 12, 2011. “We are dropping coverage of Teva Pharmaceutical Industries Ltd. (TEVA, $38) with this issue. The company’s prospects for growth have diminished with no near-term visible opportunities...
Read More

How to Find the Best Biotech Stocks

Have you ever wondered how to find great biotech stocks in a sea of hopeful but high-risk medical small caps? Well, for my latest Dick Davis Digest contributor interview, I interviewed John McCamant, the editor of a top-performing investment newsletter that’s all about the...
Read More